Research programme: congestive heart failure-gene therapy - Sanofi
Alternative Names: Vascular graft occlusion gene therapy - Sanofi ; βARKct gene therapyLatest Information Update: 31 Mar 2022
At a glance
- Originator Duke University; Genzyme Corporation
- Developer Duke University; Sanofi
- Class
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ischaemic heart disorders; Vascular graft occlusion
Most Recent Events
- 22 Jun 2005 Preclinical trials in Vascular graft occlusion in USA (unspecified route)
- 22 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the adverse events and Ischaemic heart disease pharmacodynamics section
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation